Listed by the USPTO as WEIDNER, ADAM M
Tech Center 1600 • Art Units: 1642 1645 1647 1649 1651 1674 1675 1677 1678
This examiner grants 64% of resolved cases
WEIDNER, ADAM M is a USPTO patent examiner in Tech Center 1600 and Art Unit 1642. The record includes 653 resolved cases and a 63.7% allowance rate. The median time to allowance is 866 days. Interviews correspond to a 33.6% allowance-rate lift, making interview preparation a potentially important part of prosecution strategy for applicants seeking to clarify claim scope, address technical objections, or narrow outstanding disputes.
The listed companies are The Regents of the University of California, Teneobio Inc., and Merck Patent GmbH. Their presence suggests a case mix centered on biotechnology and related life-science work. The leading firms are BakerHostetler, BALLARD SPAHR LLP, and Cermak & McGowan LLP. Applicants can use this profile to anticipate both a substantial prosecution record and a meaningful association between interviews and improved allowance outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17623913 | ANTIBODY DRUG CONJUGATE PURIFICATION | Non-Final OA | Merck Patent GmbH |
| 18581931 | AUTOIMMUNE ANTIBODIES FOR USE IN INHIBITING CANCER CELL GROWTH | Non-Final OA | The Johns Hopkins University |
| 18528645 | SYSTEMS AND METHODS FOR THE PREPARATION OF PEPTIDE-MHC-I COMPLEXES WITH NATIVE GLYCAN MODIFICATIONS | Non-Final OA | The Regents of The University of California |
| 18230480 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Final Rejection | The Regents of the University of California |
| 17799444 | PLATELET FACTORS AND COGNITIVE IMPROVEMENT | Non-Final OA | The Regents of the University of California |
| 18680465 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 18487767 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AUTOIMMUNE INDUCED CARDIAC LONG QT SYNDROME | Final Rejection | New York University |
| 18023573 | IMMUNOGENIC COMPOSITION TARGETING PHOSPHORYLATED TAU PROTEIN | Non-Final OA | OSAKA UNIVERSITY |
| 18445651 | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.7% of resolved applications examined by Adam M Weidner were allowed (653 resolved cases), compared with 38.5% across Art Unit 1642 over the last five years.
This examiner's interview lift is +33.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Adam M Weidner took 866 days on average from filing to allowance.
Adam M Weidner examines applications in Art Unit 1642 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
